Arctic Therapeutics Secures €26.5 Million for Dementia Research
Exciting news has emerged from Arctic Therapeutics as they recently announced the successful closing of an oversubscribed Series A financing round totaling €26.5 million. This significant investment will play a vital role in accelerating the company’s innovative anti-amyloid treatment designed to tackle both rare and more common forms of dementia.
The funding was sourced from an impressive syndicate of international investors, which includes influential entities such as the EIC Fund, the notably large Icelandic investment firm Kaldbakur, and Investcorp-backed Sanos Group. Additionally, the consortium features the likes of Cerebrum DAO based in Switzerland and The Lurie Family Foundation led by billionaire Jeffery Lurie, along with several renowned Icelandic institutional investors.
Focus on Dementia and Dermatological Innovations
Ivar Hakonarson, co-founder and CEO of Arctic Therapeutics, articulated the significance of these funds, highlighting their potential to drive meaningful advances in treatments for conditions ranging from familial forms of dementia to inflammatory skin diseases.
He stated, "This funding represents a critical milestone in our journey to address significant unmet medical needs, especially in dementia care and innovative dermatological treatments. The new investors not only provide financial backing but also bring in expertise that is invaluable for our progress."
Use of Funds for Clinical Development
The capital raised will primarily focus on advancing Arctic Therapeutics' frontrunner drug candidates, namely AT-001 and AT-004. The company is actively gearing up to progress these innovations through clinical trials.
Last year, the European Medicines Agency approved a pivotal Phase IIb/III trial for AT-001, aimed specifically at treating Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare and challenging form of familial dementia. The infusion of funds will enable Arctic Therapeutics to broaden the scope of AT-001 to investigate its efficacy in other types of familial dementia, and eventually Alzheimer’s disease.
The Importance of Innovative Solutions in Healthcare
The rapid advancement in understanding amyloid proteins showcases the necessity of preventing amyloid plaque formation in the brain. Hakonarson emphasized that this knowledge enhances the transformative potential of their treatment strategy, with hopes to significantly slow down or even halt the progression of neurodegenerative diseases.
Beyond dementia, Arctic Therapeutics is also set to initiate a Phase IIa trial for AT-004. This clinical study will initially target acne vulgaris before potentially expanding into other inflammatory skin conditions such as atopic dermatitis, rosacea, and psoriasis.
Strategic Board Appointments
Further solidifying its leadership, Arctic Therapeutics has appointed Jeppe Ragnar Andersen, CEO of Sanos Group, to its board of directors. Andersen pointed out the synergy between Sanos Group's dermatology expertise and Arctic Therapeutics’ focus on innovating treatments for both dermatological and neurological conditions.
He expressed enthusiasm about working closely with Arctic Therapeutics to deliver groundbreaking solutions to patients suffering from dementia-related disorders and skin diseases.
Recognition and Future Endeavors
Last year marked another accomplishment for Arctic Therapeutics when they were selected to join the prestigious EIC Scaling Club, a dedicated network aimed at propelling promising scale-ups across Europe. The club’s objective is to nurture at least 20% of its members towards achieving unicorn status.
The European Innovation Council Fund plays a crucial role by providing financial resources tailored to foster companies capable of addressing vital global challenges, such as dementia, which impacts over ten million people in Europe alone.
Svetoslava Georgieva, Chair of the EIC Fund Board, summarized the societal implications of this investment. She remarked, "Investing in innovative solutions to address the global healthcare challenge of dementia is both a responsibility and an opportunity. By partnering with Arctic Therapeutics, we aim to support transformative preventative treatments that could shift the care landscape and enhance quality of life globally.”
Frequently Asked Questions
What is the significance of the €26.5 million funding for Arctic Therapeutics?
This funding will accelerate the development of innovative treatments for dementia and inflammatory skin diseases, addressing crucial medical needs.
Which drug candidates are being advanced with this funding?
The funds will primarily support the development of AT-001 and AT-004, leading to further clinical trials and advancements in treatment capabilities.
Who are the key investors in the funding round?
A broad syndicate of international investors participated, including the EIC Fund, Kaldbakur, and Investcorp-backed Sanos Group, among others.
What clinical trials are planned for the funded drug candidates?
Arctic Therapeutics is moving forward with a pivotal trial for AT-001 targeting familial dementia, and a Phase IIa trial for AT-004 focused on acne vulgaris.
How does Arctic Therapeutics align with the EIC Scaling Club goals?
By joining the EIC Scaling Club, Arctic Therapeutics aims to leverage support and resources to scale its innovations, aspiring for significant growth and impact in the healthcare sector.
